Investors Urged to Check Claims Against LifeMD as Deadline Approaches

LifeMD Investors: Important Legal Notice

As the deadline approaches, Faruqi & Faruqi, LLP invites investors of LifeMD, Inc. to take action regarding potential legal claims. If you've acquired securities in LifeMD between May 7 and August 5, 2025, now is the time to understand your rights and options.

The deadline for filing as a lead plaintiff in a federal securities class action lawsuit against LifeMD is set for October 27, 2025. This case arises from allegations that LifeMD and its management made false or misleading statements, significantly overstating the company's competitive position and failing to correctly account for rising customer acquisition costs.

On August 5, 2025, LifeMD's financial results for the second quarter revealed a dismal outlook. They revised their revenue guidance downward, expecting totals between $250 million and $255 million, a significant drop from their prior forecast of $268 million to $275 million. Following this announcement, LifeMD's stock price plummeted nearly 44.8% in just one day.

The firm suggests that investors who suffered losses due to these misleading statements should consider contacting Faruqi & Faruqi for a consultation. Senior Partner, James (Josh) Wilson, is available to discuss individual cases and potential litigation pathways for affected investors.

Faruqi & Faruqi has a solid history of advocating for investors, having successfully recovered substantial sums across various securities cases since its establishment in 1995. With offices located in key states including New York, Pennsylvania, California, and Georgia, their expertise in securities law is well regarded.

The allegations against LifeMD are serious: the complaint asserts that executives raised revenue forecasts recklessly, which contributed to misleading investors and the substantial losses reported. To protect your rights, you must act quickly, as the window for potential legal actions is narrowing.

If you are part of the affected shareholders and want to be involved in or learn more about the class action lawsuit, please reach out to Faruqi & Faruqi through their website or by contacting Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Furthermore, anyone possessing additional information about the company's actions, including former employees or whistleblowers, is encouraged to contact the firm to bolster the investigations further. The life of this class action could potentially depend on shared insights from those intimately aware of LifeMD's practices.

Being a lead plaintiff involves having the largest financial stake in the case and actively guiding the litigation process. However, potential members do not have to take on this role to be eligible for any recovery; staying inactive will not affect their claims in any potential settlement.

For continued updates and important announcements, investors can school in via social media networks like LinkedIn and X, staying informed on progress as this case develops.

Faruqi & Faruqi stresses that every communication about your case will be handled confidentially, allowing you to discuss personal circumstances without concern. Understanding your options at this critical juncture is paramount for affected investors. Don’t delay—reach out today and explore your legal alternatives.